New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection

Vittoria, Bauso Luana; Imbesi, Chiara; Gasparo, Irene; Calì, Gabriella; Bitto, Alessandra

doi:10.3390/ph14060503

Cited by 8 publications

(2 citation statements)

References 126 publications

(144 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the combined formulation will be less toxic and the dose of the drug can also be minimized as compared to the approved formulation with less chances of drug resistance due to synergistic effect, [7,13].…”

Section: Concluding Remarks and Future Perspectivesmentioning

confidence: 99%

Reprofiling of Octogenarian Antiviral Agent: A New Avenue Venture to Discover Viral Infection

Farhana¹,

Ahmed²,

Iqbal³

et al. 2022

Antiviral Drugs - Intervention Strategies

View full text Add to dashboard Cite

Identification of a new drug molecule to a new target, specifically viral, bacterial, and fungal infection, is the prime focus of time immortal. The tridiagonal practice of drug discovery for emerging viral infection turned out to be a new venture to combat the morbidly and mortality of recent pandemics due to viral, bacterial, fungal, infection and infestation, the emerging number of viral infections day by day, the targeted therapy with the gap in assessment lead to reprofiling or repositioning available FDA-approved formulation give promising drug candidate for various infection specifically the current scenario of antiviral drug-reprofiling through drug designing approach, the emergence of resistance to existing antiviral drugs and re-emerging viral infections are the greatest challenges in antiviral drug discovery. The reprofiling approach is a worthy strategy to get the potent antiviral in brief span of time to overcome the challenges in antiviral therapy. The present chapter will be another representing the most promising results of reprofiling (Repositioning or repurposing) approach in the treatment of various infectious diseases.

show abstract

Section: Concluding Remarks and Future Perspectivesmentioning

confidence: 99%

Reprofiling of Octogenarian Antiviral Agent: A New Avenue Venture to Discover Viral Infection

Farhana¹,

Ahmed²,

Iqbal³

et al. 2022

Antiviral Drugs - Intervention Strategies

View full text Add to dashboard Cite

show abstract

“…Several medicines are currently undergoing phase 3 and 4 clinical trials [4,5]. Antiviral agents, antibodies, cellular molecules, RNAbased drugs, and repurposing therapies have all been mentioned as preclinical therapeutic candidates [6]. Other methods of treatment include antimalarial, proteinaceous, interferon, anti-inflammatory, and antibiotic receptor modifying drugs [7].…”

Section: Introductionmentioning

confidence: 99%

A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors

Singh

Han

Choi

et al. 2023

CIMB

View full text Add to dashboard Cite

SARS-CoV-2 (severe acute respiratory syndrome) is highly infectious and causes severe acute respiratory distress syndrome (SARD), immune suppression, and multi-organ failure. For SARS-CoV-2, only supportive treatment options are available, such as oxygen supportive therapy, ventilator support, antibiotics for secondary infections, mineral and fluid treatment, and a significant subset of repurposed effective drugs. Viral targeted inhibitors are the most suitable molecules, such as ACE2 (angiotensin-converting enzyme-2) and RBD (receptor-binding domain) protein-based inhibitors, inhibitors of host proteases, inhibitors of viral proteases 3CLpro (3C-like proteinase) and PLpro (papain-like protease), inhibitors of replicative enzymes, inhibitors of viral attachment of SARS-CoV-2 to the ACE2 receptor and TMPRSS2 (transmembrane serine proteinase 2), inhibitors of HR1 (Heptad Repeat 1)–HR2 (Heptad Repeat 2) interaction at the S2 protein of the coronavirus, etc. Targeting the cathepsin L proteinase, peptide analogues, monoclonal antibodies, and protein chimaeras as RBD inhibitors interferes with the spike protein’s ability to fuse to the membrane. Targeting the cathepsin L proteinase, peptide analogues, monoclonal antibodies, and protein chimaeras as RBD inhibitors interferes with the spike protein’s ability to fuse to the membrane. Even with the tremendous progress made, creating effective drugs remains difficult. To develop COVID-19 treatment alternatives, clinical studies are examining a variety of therapy categories, including antibodies, antivirals, cell-based therapy, repurposed diagnostic medicines, and more. In this article, we discuss recent clinical updates on SARS-CoV-2 infection, clinical characteristics, diagnosis, immunopathology, the new emergence of variant, SARS-CoV-2, various approaches to drug development and treatment options. The development of therapies has been complicated by the global occurrence of many SARS-CoV-2 mutations. Discussion of this manuscript will provide new insight into drug pathophysiology and drug development.

show abstract

Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen

Wang

et al. 2022

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection

Cited by 8 publications

References 126 publications

Reprofiling of Octogenarian Antiviral Agent: A New Avenue Venture to Discover Viral Infection

Reprofiling of Octogenarian Antiviral Agent: A New Avenue Venture to Discover Viral Infection

A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors

Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen

Contact Info

Product

Resources

About